ESMO 2024 | EV-302: advancing treatment for metastatic urothelial carcinoma
Vadim Koshkin, MD, UCSF, San Francisco, CA, highlights the significant impact of the Phase III EV-302 trial (NCT04223856), which demonstrated that the combination of enfortumab vedotin and pembrolizumab nearly doubled median overall survival for patients with metastatic urothelial carcinoma in the first-line setting. Despite these advancements, many patients are not cured, prompting the need for ongoing research into treatment intensification and de-intensification strategies. Biomarkers will be necessary to identify patient who may require more intensive treatment or who could benefit from a finite duration of enfortumab vedotin. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
